“Sanofi has the best selling long-acting insulin, Lantus, but its fast-acting insulin, Apidra, has fared poorly in the marketplace. By substituting LINject for Apidra, Sanofi can offer a more compelling combination of ultra-fast and long acting insulins."
I agree. SNY has a hard time competing with Novo Nordisk in the institutional setting because they have a wide variety of diabetes medication to give significant discounts from an aquisition stand point.
Linject may be a good fit in that scenario. If the Genzyme bid falls through they will be actively looking for other opportunities.